Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Dr. ChatGPT? Meet the new AI medical chatbot

Jonathon Brown Jonathon Brown, The Market Online
0 Comments| June 15, 2023

{{labelSign}}  Favorites
{{errorMessage}}

  • DiagnaMed (CSE:DMED) has launched Dr. GenAI, a generative artificial intelligence medical chatbot powered by OpenAI’s ChatGPT
  • Dr. GenAI is designed as a personal medical chatbot to give people a new way to obtain fast and personalized medical information based on a person’s unique medical condition
  • Dr. GenAI is the company’s third commercial product from its Health GenAI division, which is focused on developing and commercializing a suite of generative AI health applications.
  • DiagnaMed Holdings Stocks (DMED) opened trading at $0.075 per share

DiagnaMed (CSE:DMED) has launched Dr. GenAI, a generative artificial intelligence medical chatbot powered by OpenAI’s ChatGPT.

Designed as a personal medical chatbot to give people a new way to obtain fast and personalized medical information based on a person’s unique medical condition, Dr. GenAI offers a “personal” chat that can learn about someone using their medical information.

Click to enlarge

The company stressed that Dr. GenAI is not a replacement for doctors and can be prone to errors, but it aims to encourage a person to be more active in their overall health care.

Dr. GenAI is the company’s third commercial product from its Health GenAI division, which is focused on developing and commercializing a suite of generative AI health applications.

DiagnaMed’s Chairman and CEO, Fabio Chianelli commented that this generative AI health solution was designed for people seeking health information based on their unique medical conditions.

“Dr. GenAI aligns with our objective of developing and commercializing OpenAI ChatGPT powered solutions for the healthcare market and incorporating them into our CERVAI generative AI brain health platform.”

DiagnaMed Holdings is an AI-driven digital health company focusing on improving brain health for mental health and neurodegenerative disorders. The company is developing its BRAIN AGE AI Product Suite, an electroencephalogram-based (EEG) artificial intelligence solution to detect an individual’s brain age, and the Brain Health Digital Platform for clinical and home use. The company recently launched PalGPT.ai, a generative AI brain health solution powered by OpenAI’s ChatGPT for people seeking an AI companion to have meaningful private conversations, friendly advice and share inner thoughts. Click here to read more.

DiagnaMed Holdings Corp. (DMED) opened trading at $0.075 per share.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.




{{labelSign}}  Favorites
{{errorMessage}}


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company